Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | ANPEP | P15144 | 4/20 | 0.50 |
| ▸ | LAP3 | P28838 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.47 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.47 |
| ▸ | FDPS | P14324 | 1/20 | 0.47 |
| ▸ | ACP3 | P15309 | 1/20 | 0.44 |
| ▸ | PGK1 | P00558 | 1/20 | 0.43 |
| ▸ | PGK2 | P07205 | 1/20 | 0.43 |
| ▸ | CFTR | P13569 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzylphosphonic Acid SCHEMBL44318 | 0.80 | HPGD (0.60) | HPGDANPEPLAP3TSHRERAP1 | |
| SCHEMBL10424306 | 0.80 | HPGD (0.54) | HPGDANPEPLAP3TSHRERAP1 | |
| SCHEMBL497159 | 0.80 | HPGD (0.60) | HPGDANPEPLAP3TSHRERAP1 | |
| Benzylphosphonic Acid SCHEMBL11474641 | 0.78 | HPGD (0.58) | HPGDANPEPLAP3TSHRACP3 | |
| SCHEMBL6683645 | 0.78 | HPGD (0.46) | HPGDANPEPLAP3TSHRERAP1 | |
| Benzylphosphonic Acid SCHEMBL915222 | 0.78 | HPGD (0.58) | HPGDANPEPLAP3TSHRACP3 | |
| SCHEMBL17004009 | 0.78 | HPGD (0.58) | HPGDANPEPLAP3TSHRERAP1 | |
| SCHEMBL6310521 | 0.78 | HPGD (0.58) | HPGDANPEPLAP3TSHRERAP1 | |
| Benzylphosphonic Acid SCHEMBL5332218 | 0.78 | HPGD (0.58) | HPGDANPEPLAP3TSHRACP3 | |
| Benzylphosphonic Acid SCHEMBL11339355 | 0.78 | HPGD (0.58) | HPGDANPEPLAP3TSHRACP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2009544611-A | — | — | 2009-12-17 | — | — | JP | claimed |
| EP-2049124-A2 | PHOSPHORUS DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | Merck & Co., Inc. (US) | 2009-04-22 | — | — | EP | claimed |
| WO-2008010985-A2 | PHOSPHORUS DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | MERCK & CO., INC. (US) | 2008-01-24 | — | — | WO | claimed |
| US-10131681-B2 | Aminophosphinic derivatives that can be used in the treatment of pain | PHARMALEADS (FR) | 2018-11-20 | — | — | US | disclosed |
| CN-108368147-A | Nucleotide for treating cancer | 南方研究院 | 2018-08-03 | — | — | CN | disclosed |
| US-20140161839-A1 | AMINOPHOSPHINIC DERIVATIVES THAT CAN BE USED IN THE TREATMENT OF PAIN | PHARMALEADS (FR) | 2014-06-12 | — | — | US | disclosed |
| US-8703747-B2 | Aminophosphinic derivatives that can be used in the treatment of pain | PHARMALEADS (FR) | 2014-04-22 | — | — | US | disclosed |
| US-20110124601-A1 | AMINOPHOSPHINIC DERIVATIVES THAT CAN BE USED IN THE TREATMENT OF PAIN | PHARMALEADS | 2011-05-26 | — | — | US | disclosed |
| EP-2049124-A2 | PHOSPHORUS DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | Merck & Co., Inc. (US) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008010985-A2 | PHOSPHORUS DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | MERCK & CO., INC. (US) | 2008-01-24 | — | — | WO | disclosed |
| US-6737416-B2 | THROMBOLYTIC AGENT HAVING HIGHER SAFETY | MEIJI SEIKA KAISHA LTD. (JP) | 2004-05-18 | — | — | US | disclosed |
| US-6576627-B1 | Such as 7-amino-2-((2-methyl-1-(3-phenylpropanoylamino)-propyl)hydroxyphosphinoyl) -methylheptanoic acid; thrombotic disease | MEIJI SEIKA KAISHA LTD. (JP) | 2003-06-10 | — | — | US | disclosed |
| EP-1152004-B1 | Phosphonic acid derivatives having carboxypeptidase B inhibitory action | MEIJI SEIKA KAISHA (JP) | 2003-05-07 | — | — | EP | disclosed |
| US-6391866-B1 | ANALGESICS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2002-05-21 | — | — | US | disclosed |
| EP-1174434-A1 | Phosphonic acid derivative having inhibitory activity against carboxypeptidase B | MEIJI SEIKA KAISHA LTD. (JP) | 2002-01-23 | — | — | EP | disclosed |
| CN-1077439-C | Labeled chemotactic peptides for imaging of sites of infection or inflammation lesions | GEN HOSPITAL CORP (US) | 2002-01-09 | — | — | CN | disclosed |
| EP-1152004-A1 | PHOSPHONIC ACID DERIVATIVES HAVING CARBOXYPEPTIDASE B INHIBITORY ACTIVITY | MEIJI SEIKA KAISHA LTD. (JP) | 2001-11-07 | — | — | EP | disclosed |
| US-5792444-A | ADMINISTERING LABELED CHEMOTACTIC PEPTIDE WHICH ACCUMULATES AT SITE OF INFECTION OR INFLAMMATION | THE GENERAL HOSPITAL CORPORATION (US) | 1998-08-11 | — | — | US | disclosed |
| CN-1141002-A | Labeled chemotactic peptides for imaging of sites of infection or inflammation lesions | GEN HOSPITAL CORP (US) | 1997-01-22 | — | — | CN | disclosed |
| US-5266552-A | Biological antigrowth agents for plants | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124601-A1 | AMINOPHOSPHINIC DERIVATIVES THAT CAN BE USED IN THE TREATMENT OF PAIN | OPRM1, HRH3, HRH4 | HPGD 2728/4885ANPEP 2038/4885LAP3 2527/4885 |
| US-10131681-B2 | Aminophosphinic derivatives that can be used in the treatment of pain | OPRM1, HRH3, HRH4 | HPGD 2901/4885ANPEP 2062/4885LAP3 2472/4885 |
| US-20140161839-A1 | AMINOPHOSPHINIC DERIVATIVES THAT CAN BE USED IN THE TREATMENT OF PAIN | OPRM1, HRH3, HRH4 | HPGD 2901/4885ANPEP 2062/4885LAP3 2472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.